Many products of Jingfeng pharmaceutical have been approved anda international high-end characteristic generic drugs have been successively launched

Shanghai stock exchange news (reporter Qi Doudou) Jingfeng pharmaceutical international high-end characteristic generic drugs have entered the harvest period After prednisone tablets of 10mg, 20mg and 50mg were approved as American generic drugs, prednisone tablets of 2.5mg/5mg received the approval of American generic drug application (anda) again The approval of amphetamine mixed salt oral tablets shows the high level of R & D and production barriers of the company Jingfeng pharmaceutical announced in the morning of December 11 that its holding subsidiary Shangjin and Tianjin Jinyao Group Co., Ltd.'s joint venture in the United States, gene York pharmaceuticals Group LLC, applied to the U.S FDA for approval of the U.S generic application of prednisone tablets, which means that the above-mentioned company can produce and sell the product in the U.S market According to the announcement, prednisone tablets are used to treat the symptoms of adrenocortical hypofunction, active rheumatism, rheumatoid arthritis and systemic lupus erythematosus At present, the main producers in the U.S market are westward, vintage, jubilant, Actavis, etc According to IMS data, the sales volume of prednisone tablets in the U.S market in 2017 was about $139 million, while the sales volume in the U.S market in 2016 and 2015 were $134 million and $139 million, respectively Jingfeng pharmaceutical said that the approval number of prednisone tablets obtained from FDA indicates that the company has the qualification to sell the product in the U.S market, which will have a positive impact on the company's expansion of the U.S pharmaceutical market and improvement of the company's performance Since this year, Jingfeng pharmaceutical adheres to the concept of "consolidating the foundation, technological innovation and sustainable development", and adheres to the industrialization road of high-end characteristic imitation innovative drugs, which is in line with international standards The approval of the 2.5mg/5mg prednisone tablet has become the third anda approval of the company this year On December 10, Jingfeng pharmaceutical announced that the company's holding subsidiary anda, an amphetamine mixed salt oral tablet, which has yet to be declared to the U.S FDA, has been approved The company can produce and sell the product in the U.S market In the view of the insiders, it only takes 10 months from application to approval of the amphetamine mixed salt oral tablet project, which is called "goal date" It is understood that amphetamine mixed salt is a powerful central nervous system stimulant, which is used to treat attention deficit hyperactivity disorder, narcolepsy and extreme obesity As amphetamine mixed salt oral tablet is a tube control drug, its R & D and production barriers in the United States are high, which are not only reviewed by FDA regulations, but also regulated by strict drug abuse agencies At present, the main manufacturers in the United States market include tava, Aurobindo, mylan, etc According to IMS data, the sales volume of amphetamine mixed salt oral tablets in the U.S market in 2018 was about $367 million, compared with $416 million in 2017 Jingfeng pharmaceutical said that the approval number of amphetamine mixed salt oral tablets obtained from the US FDA indicates that the company has the qualification to sell the product in the US market, which will have a positive impact on the company's expansion of the US pharmaceutical market and improvement of its performance.